Invitae Corp Stock
Your prediction
Invitae Corp Stock
For the coming years our community has positive and negative things to say abot the Invitae Corp stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Invitae Corp in the next few years
Pros
?
M***** P*******
?
S********** s********
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Invitae Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Invitae Corp | - | - | - | - | - | - | - |
| Ironwood Pharmaceuticals | 0.690% | -2.685% | -8.228% | -22.872% | -28.922% | -21.622% | - |
| Sage Therapeutics Inc. | -1.020% | 7.851% | -25.000% | -69.792% | -34.750% | -79.867% | - |
| Novocure Ltd | -2.010% | 1.864% | -20.671% | -80.817% | -19.615% | -93.244% | - |
Comments
News
Is Invitae Stock a Buy Now?
Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to
Invitae (NVTA) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Invitae (NYSE: NVTA)Q3 2023 Earnings CallNov 08, 2023, 4:30 p.m. ET
Operator
Source Fool.com
3 Things About Invitae Every Smart Investor Knows
Genetic-testing company, Invitae (NYSE: NVTA), isn't as easy to understand as it might seem. After more than a year of pivoting and scaling down its operations, changing its leadership, and